{
    "ticker": "CYCN",
    "name": "Cyclo Therapeutics, Inc.",
    "description": "Cyclo Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. Founded in 2016 and headquartered in Gainesville, Florida, the company specializes in utilizing its proprietary hydroxypropyl beta-cyclodextrin (HPBCD) technology to potentially treat conditions like Alzheimer's disease and other lysosomal storage disorders. Cyclo Therapeutics is dedicated to addressing significant unmet medical needs through research and clinical trials, aiming to enhance the quality of life for patients suffering from debilitating neurological conditions. The company's lead product candidate, Trappsol\u00ae Cyclo\u2122, is currently being investigated in clinical trials for its efficacy in improving cognitive function in patients with Alzheimer's disease. Cyclo Therapeutics is committed to advancing scientific understanding and developing effective therapies, leveraging collaborations with academic institutions and research organizations to further its mission. The company's vision is to bring hope to patients and families affected by these diseases by pioneering therapeutic options that can fundamentally change the landscape of treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Gainesville, Florida, USA",
    "founded": "2016",
    "website": "https://www.cyclotherapeutics.com",
    "ceo": "N. Scott Fine",
    "social_media": {
        "twitter": "https://twitter.com/CycloTherapeutics",
        "linkedin": "https://www.linkedin.com/company/cyclo-therapeutics"
    },
    "investor_relations": "https://www.cyclotherapeutics.com/investors",
    "key_executives": [
        {
            "name": "N. Scott Fine",
            "position": "CEO"
        },
        {
            "name": "Mary A. S. Gibbons",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Trappsol\u00ae Cyclo\u2122"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cyclo Therapeutics, Inc. | Innovative Treatments for Neurodegenerative Diseases",
        "meta_description": "Learn about Cyclo Therapeutics, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative disorders using innovative HPBCD technology.",
        "keywords": [
            "Cyclo Therapeutics",
            "Neurodegenerative Diseases",
            "Alzheimer's Treatment",
            "HPBCD Technology",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Cyclo Therapeutics known for?",
            "answer": "Cyclo Therapeutics is known for its innovative treatments for neurodegenerative diseases, particularly through its lead product candidate, Trappsol\u00ae Cyclo\u2122."
        },
        {
            "question": "Who is the CEO of Cyclo Therapeutics?",
            "answer": "N. Scott Fine is the CEO of Cyclo Therapeutics, Inc."
        },
        {
            "question": "Where is Cyclo Therapeutics headquartered?",
            "answer": "Cyclo Therapeutics is headquartered in Gainesville, Florida, USA."
        },
        {
            "question": "What is Trappsol\u00ae Cyclo\u2122?",
            "answer": "Trappsol\u00ae Cyclo\u2122 is a proprietary formulation being investigated for its potential to improve cognitive function in patients with Alzheimer's disease."
        },
        {
            "question": "When was Cyclo Therapeutics founded?",
            "answer": "Cyclo Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "PTCT",
        "AVXL",
        "ADMS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}